NCT07170293 2025-09-12Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid TumorsTianjin Medical University Second HospitalPhase 2 Recruiting15 enrolled
NCT00096941 2015-06-11A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer StudyGenentech, Inc.Phase 2 Completed3 enrolled 5 charts